| Dr Frederick Dean Poage, DO | |
|
8960 Hillside Rd, Amarillo, TX 79119-7323 | |
| (063) 517-7068 | |
| Not Available |
| Full Name | Dr Frederick Dean Poage |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 10 Years |
| Location | 8960 Hillside Rd, Amarillo, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720407125 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | Q6086 (Texas) | Secondary |
| 207P00000X | Emergency Medicine | Q6086 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Home Care Connections | Amarillo, TX | Home health agency |
| Northwest Texas Hospital | Amarillo, TX | Hospital |
| Baptist St Anthony's Hospital | Amarillo, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hunt Richardson Group Llc | 7911373279 | 3 |
| Nes Southwest Medical Services Inc. | 9234520800 | 39 |
| Texas Tech University Health Sciences Center Amarillo | 9234037847 | 71 |
News Archive
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
NeuroVive's anti-viral preclinical program, with compound designated NVP018, has generated significant data indicating that NVP018 has the potential to become an effective alternative or addition to current drugs for treating chronic hepatitis B infections.
A nationwide advertising campaign launches today (Friday 22 October) as part of the government's call to the public to get their COVID-19 booster and flu jabs, to protect themselves and their loved ones this winter.
RF Surgical Systems, Inc., the market leader in the prevention and detection of retained surgical sponges, today announced the availability of the RF Assure™ Detection System Model 200.
Studies show wearing masks and social distancing can contain the spread of the COVID-19 virus, but their combined effectiveness was not precisely known.
› Verified 9 days ago
| Entity Name | Texas Tech University Health Sciences Center Amarillo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013942150 PECOS PAC ID: 9234037847 Enrollment ID: O20031220000051 |
News Archive
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
NeuroVive's anti-viral preclinical program, with compound designated NVP018, has generated significant data indicating that NVP018 has the potential to become an effective alternative or addition to current drugs for treating chronic hepatitis B infections.
A nationwide advertising campaign launches today (Friday 22 October) as part of the government's call to the public to get their COVID-19 booster and flu jabs, to protect themselves and their loved ones this winter.
RF Surgical Systems, Inc., the market leader in the prevention and detection of retained surgical sponges, today announced the availability of the RF Assure™ Detection System Model 200.
Studies show wearing masks and social distancing can contain the spread of the COVID-19 virus, but their combined effectiveness was not precisely known.
› Verified 9 days ago
| Entity Name | Concord Medical Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083630610 PECOS PAC ID: 0446296818 Enrollment ID: O20050707000531 |
News Archive
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
NeuroVive's anti-viral preclinical program, with compound designated NVP018, has generated significant data indicating that NVP018 has the potential to become an effective alternative or addition to current drugs for treating chronic hepatitis B infections.
A nationwide advertising campaign launches today (Friday 22 October) as part of the government's call to the public to get their COVID-19 booster and flu jabs, to protect themselves and their loved ones this winter.
RF Surgical Systems, Inc., the market leader in the prevention and detection of retained surgical sponges, today announced the availability of the RF Assure™ Detection System Model 200.
Studies show wearing masks and social distancing can contain the spread of the COVID-19 virus, but their combined effectiveness was not precisely known.
› Verified 9 days ago
| Entity Name | Ess Of South Texas Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295128247 PECOS PAC ID: 9739491176 Enrollment ID: O20150629000248 |
News Archive
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
NeuroVive's anti-viral preclinical program, with compound designated NVP018, has generated significant data indicating that NVP018 has the potential to become an effective alternative or addition to current drugs for treating chronic hepatitis B infections.
A nationwide advertising campaign launches today (Friday 22 October) as part of the government's call to the public to get their COVID-19 booster and flu jabs, to protect themselves and their loved ones this winter.
RF Surgical Systems, Inc., the market leader in the prevention and detection of retained surgical sponges, today announced the availability of the RF Assure™ Detection System Model 200.
Studies show wearing masks and social distancing can contain the spread of the COVID-19 virus, but their combined effectiveness was not precisely known.
› Verified 9 days ago
| Entity Name | Town Square Emergency Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457890402 PECOS PAC ID: 9931485604 Enrollment ID: O20170412000070 |
News Archive
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
NeuroVive's anti-viral preclinical program, with compound designated NVP018, has generated significant data indicating that NVP018 has the potential to become an effective alternative or addition to current drugs for treating chronic hepatitis B infections.
A nationwide advertising campaign launches today (Friday 22 October) as part of the government's call to the public to get their COVID-19 booster and flu jabs, to protect themselves and their loved ones this winter.
RF Surgical Systems, Inc., the market leader in the prevention and detection of retained surgical sponges, today announced the availability of the RF Assure™ Detection System Model 200.
Studies show wearing masks and social distancing can contain the spread of the COVID-19 virus, but their combined effectiveness was not precisely known.
› Verified 9 days ago
| Entity Name | Truepartners Northwest Emergency Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912447319 PECOS PAC ID: 4880970466 Enrollment ID: O20170413002085 |
News Archive
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
NeuroVive's anti-viral preclinical program, with compound designated NVP018, has generated significant data indicating that NVP018 has the potential to become an effective alternative or addition to current drugs for treating chronic hepatitis B infections.
A nationwide advertising campaign launches today (Friday 22 October) as part of the government's call to the public to get their COVID-19 booster and flu jabs, to protect themselves and their loved ones this winter.
RF Surgical Systems, Inc., the market leader in the prevention and detection of retained surgical sponges, today announced the availability of the RF Assure™ Detection System Model 200.
Studies show wearing masks and social distancing can contain the spread of the COVID-19 virus, but their combined effectiveness was not precisely known.
› Verified 9 days ago
| Entity Name | Nes Southwest Medical Services Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093487449 PECOS PAC ID: 9234520800 Enrollment ID: O20211216001478 |
News Archive
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
NeuroVive's anti-viral preclinical program, with compound designated NVP018, has generated significant data indicating that NVP018 has the potential to become an effective alternative or addition to current drugs for treating chronic hepatitis B infections.
A nationwide advertising campaign launches today (Friday 22 October) as part of the government's call to the public to get their COVID-19 booster and flu jabs, to protect themselves and their loved ones this winter.
RF Surgical Systems, Inc., the market leader in the prevention and detection of retained surgical sponges, today announced the availability of the RF Assure™ Detection System Model 200.
Studies show wearing masks and social distancing can contain the spread of the COVID-19 virus, but their combined effectiveness was not precisely known.
› Verified 9 days ago
| Entity Name | Hunt Richardson Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952020083 PECOS PAC ID: 7911373279 Enrollment ID: O20221012001509 |
News Archive
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
NeuroVive's anti-viral preclinical program, with compound designated NVP018, has generated significant data indicating that NVP018 has the potential to become an effective alternative or addition to current drugs for treating chronic hepatitis B infections.
A nationwide advertising campaign launches today (Friday 22 October) as part of the government's call to the public to get their COVID-19 booster and flu jabs, to protect themselves and their loved ones this winter.
RF Surgical Systems, Inc., the market leader in the prevention and detection of retained surgical sponges, today announced the availability of the RF Assure™ Detection System Model 200.
Studies show wearing masks and social distancing can contain the spread of the COVID-19 virus, but their combined effectiveness was not precisely known.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Frederick Dean Poage, DO 8960 Hillside Rd, Amarillo, TX 79119-7323 Ph: (806) 351-7706 | Dr Frederick Dean Poage, DO 8960 Hillside Rd, Amarillo, TX 79119-7323 Ph: (063) 517-7068 |
News Archive
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
NeuroVive's anti-viral preclinical program, with compound designated NVP018, has generated significant data indicating that NVP018 has the potential to become an effective alternative or addition to current drugs for treating chronic hepatitis B infections.
A nationwide advertising campaign launches today (Friday 22 October) as part of the government's call to the public to get their COVID-19 booster and flu jabs, to protect themselves and their loved ones this winter.
RF Surgical Systems, Inc., the market leader in the prevention and detection of retained surgical sponges, today announced the availability of the RF Assure™ Detection System Model 200.
Studies show wearing masks and social distancing can contain the spread of the COVID-19 virus, but their combined effectiveness was not precisely known.
› Verified 9 days ago
Joseph D Hollingsworth, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1600 Wallace Blvd, Baptist Saint Anthony's Hospital, Amarillo, TX 79106 Phone: 806-212-2000 | |
Mike Preston Berry Jr., M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1600 Wallace Blvd, Amarillo, TX 79106 Phone: 806-212-2000 Fax: 806-212-2735 | |
Christopher M Bradburry, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1501 S Coulter St, Amarillo, TX 79106 Phone: 806-354-1000 | |
Matthew W Turney, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2101 S Coulter St, Amarillo, TX 79106 Phone: 806-350-7744 Fax: 806-350-7776 | |
Alicia Irene Balderas, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1616 S Kentucky St Ste B100, Amarillo, TX 79102 Phone: 806-355-8900 | |
Darrell I Morgan, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3440 Bell St, Suite 320, #186, Amarillo, TX 79109 Phone: 806-322-3230 | |
Robert N. Reddix Jr., MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3501 S Soncy Rd Ste 104, Amarillo, TX 79119 Phone: 806-398-3627 Fax: 806-351-7801 |